Medicine
Cinvanti 130 mg/18 mL injectable emulsion
Cinvanti 130 mg/18 mL injectable emulsion is a prescription medicine containing Aprepitant for intravenous use, marketed by Heron Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
CINVANTI injectable emulsion vials must be refrigerated, store at 2°C-8°C…
Key facts
- Active ingredient (INN)
- Aprepitant
- Brand
- Cinvanti
- Strength
- 130 mg/18 mL
- Dosage form
- Injectable emulsion
- Route
- Intravenous
- Packs
- 1 vial of 18 mL
- Marketing authorisation holder
- Heron Therapeutics
- Manufacturer
- Heron Therapeutics
- Origin register
- US FDA, United States
- Storage
- CINVANTI injectable emulsion vials must be refrigerated, store at 2°C-8°C (36°F-46°F). Do not freeze. CINVANTI injectable emulsion vials can remain at room temperature up to 60 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A04AD12 Fosaprepitant
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 January 2018
- Identifiers
- RxCUI 1995150, 1995155DailyMed set ID 4c218d3a-a508-4abc-9ed8-a6e8e191d1b4NDC 47426-201Application NDA209296
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 18 mL in 1 vial, glass | 47426-201-01 | Heron Therapeutics | 3 January 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Aprepitant
Clinical summary
Aprepitant is a substance P/neurokinin-1 receptor antagonist. It is available as capsules, injectable emulsion and kits for oral and intravenous use. MedsAcross supplies Aprepitant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AprepitantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMEND prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Emend: European public assessment report (EPAR) · European Medicines Agency
Need Cinvanti 130 mg/18 mL injectable emulsion for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.